Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: Real-World Experience from a Retrospective Multicenter Observational Study

(1) Background: Tofacitinib is approved in Europe for the treatment of adults with moderately to severely active ulcerative colitis since 2018. Real-world efficacy and safety data are currently scarce. (2) Methods: We performed a retrospective multicenter study at three German tertiary outpatient cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Peter, Globig, Anna-Maria, Thomann, Anne K., Grigorian, Maximilian, Krisam, Johannes, Hasselblatt, Peter, Reindl, Wolfgang, Gauss, Annika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408885/
https://www.ncbi.nlm.nih.gov/pubmed/32664204
http://dx.doi.org/10.3390/jcm9072177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408885/
https://www.ncbi.nlm.nih.gov/pubmed/32664204
http://dx.doi.org/10.3390/jcm9072177

Ejemplares similares